Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

136
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
136
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

106
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
106
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

75
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

102
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
102
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting ACKR3/CXCR7 Enhances Platelet Anticoagulant Acylcarnitines and Modulates Procoagulant Function.

Blood·2026
Same author

A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence.

NPJ breast cancer·2026
Same author

Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study.

EClinicalMedicine·2026
Same author

Drug targeting of the monocarboxylate transporter MCT4 is a novel treatment strategy for metastatic ccRCC.

Pharmacological research·2025
Same author

Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.

Clinical pharmacology and therapeutics·2025
Same author

Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Related Experiment Video

Updated: Mar 22, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

25.0K

Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.

Harald Staiger1, Elke Schaeffeler1, Matthias Schwab1

  • 1Interfaculty Centre for Pharmacogenomics and Pharma Research at the University of Tübingen, Tübingen, Germany.

The Review of Diabetic Studies : RDS
|April 26, 2016
PubMed
Summary

Pharmacogenetics explores how genetic variations affect drug responses in type 2 diabetes treatment. This review details gene-drug interactions for common diabetes medications, aiming to personalize therapy and reduce treatment failure.

More Related Videos

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

3.4K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K

Related Experiment Videos

Last Updated: Mar 22, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

25.0K
Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

3.4K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K

Area of Science:

  • Pharmacogenetics and Clinical Pharmacology
  • Genomics and Precision Medicine

Background:

  • Interindividual variability in drug response is common in clinical practice.
  • Pharmacogenetics investigates genetic impacts on treatment outcomes and adverse drug reactions.
  • Type 2 diabetes pharmacogenetics is a growing field, examining genetic influences on drug efficacy and safety.

Purpose of the Study:

  • To review current knowledge on gene-drug interactions in type 2 diabetes pharmacotherapy.
  • To summarize findings on genetic variants affecting pharmacokinetics and pharmacodynamics of diabetes drugs.
  • To highlight novel candidate genes and critically appraise the clinical relevance of pharmacogenetics in type 2 diabetes.

Main Methods:

  • Literature review of pharmacogenetic studies related to type 2 diabetes medications.
  • Analysis of gene-drug interactions involving drug transporters, targets, and signaling pathways.
  • Inclusion of findings from genome-wide association studies and candidate gene approaches.

Main Results:

  • Gene-drug interactions identified for metformin, incretin mimetics, gliptins, and gliflozins.
  • Genetic variants influence pharmacokinetics (e.g., transporters) and pharmacodynamics (e.g., drug targets).
  • Both known type 2 diabetes risk genes and novel genes are implicated in drug response.

Conclusions:

  • Pharmacogenetics offers potential for personalized type 2 diabetes treatment strategies.
  • Clinical relevance of current pharmacogenetic findings needs improvement.
  • Future efforts should focus on validating novel genes and integrating pharmacogenetics into clinical decision-making to minimize treatment failure.